Gene and cell therapies (GCTs) can target the kidney to treat congenital, acute or chronic diseases affecting this organ.

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to ...

A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces ...

The U.S. Centers for Medicare & Medicaid Services reported a request for information for a modernized digital health ...

Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve ...

Just two months after Inozyme Pharma Inc. cut its workforce by 25% and prioritized activities to focus on a BLA filing for INZ-701 for ENPP1 deficiency, interim phase III data from its Energy 3 trial ...

Using a customized gene editing therapy, researchers at the Children’s Hospital of Philadelphia have reported success in treating an infant with a severe metabolic disorder. Kiran Musunuru, Barry J.

PhaseV Inc. raised $50 million in a series A funding round to further develop its machine learning (ML) platform which helps companies reduce the cost and duration of clinical trials, and increase ...

Recognizing the potential legal challenges to U.S. President Donald Trump’s executive order calling for most-favored-nation (MFN) prescription drug pricing and the limits of that order, several ...

Royal Philips NV unveiled its Future Health Index report for 2025, and it reveals the widening trust gap between health care professionals and patients concerning the adoption of AI in health care.

Newco Avidicure NV arrived on the scene with a hefty $50 million in seed funding to advance novel antibody formats the company says will surpass the best qualities of first-generation antibodies, ...

Researchers at the China Pharmaceutical University have developed a series of highly active receptor-interacting protein kinase 1 (RIPK1) inhibitors with potent anti-inflammatory activity. RIPK1 is a ...